Rheumatoid Arthritis Clinical and Flow Cytometry Biomarker Data

ELISA and flow cytometry analysis provides FGL2 protein levels and immune cell subset proportions for a cohort of rheumatoid arthritis patients. The dataset includes pre-treatment clinical data, such as DAS28 disease activity scores derived from clinician evaluations. RONG HUANG published this research data on figshare in April 2026.

Use Cases

• Correlate FGL2 biomarker levels detected by ELISA with DAS28 clinical activity scores.
• Analyze relationships between flow cytometry-derived immune cell subset proportions and patient laboratory test results.
• Model pre-treatment disease state using combined clinical evaluation data and protein biomarker measurements.

Strengths

• Includes multiple data modalities: clinical scores (DAS28), protein levels (FGL2), and cell population data from flow cytometry.
• Data is explicitly linked to a pre-treatment patient cohort for rheumatoid arthritis research.
• Published under a permissive CC-BY-4.0 license for reuse.

Limitations

• The dataset is very small at 15.7 KB, indicating a limited sample size likely under 100 patients.
• Contains only pre-treatment data, lacking longitudinal or post-treatment follow-up information.
• Geographic and demographic coverage of the patient cohort is unspecified, limiting generalizability.

Provenance

Source

Research data from author RONG HUANG, published on figshare.

Collection Method

FGL2 data from ELISA assays; cell subset proportions from flow cytometry; clinical DAS28 scores from clinician evaluations; other clinical data from patient lab tests.

Freshness

Last updated in April 2026, indicating recent data publication.